Geneuro Forum WKN: A2AHDP ISIN: CH0308403085 Kürzel: GEM Forum: Aktien User: EuGeHe

💰

Da weiß wohl einer mehr als wir🤭

Nicht schlecht der Anstieg heute, hoffe mal es geht so weiter

Bankrupti ??? Chapter 11??

Autsch...alle Mitarbeiter werden wohl entlassen

Genesis AI - kurz vor Ankündigung neuer Aufträge!!! Es gibt auch nur 6 million aktien im Umlauf… Mein Rat , beobachtet es 😏

Warte noch ein wenig mit dem Verkauf —> Glaube da geht noch was ….

Ja, leider. Ich würde hier gerne rausgehen und mein Minus minimieren...

Ja, leider. Ich würde hier gerne rausgehen und mein Minus minimieren...

+27 % —> Handel ausgesetzt

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has, in a May 26, 2025, judgment, granted GeNeuro SA a four-month definitive debt-restructuring moratorium, under the continued supervision of the court-appointed commissary. Definitive Debt-Restructuring Moratorium As previously announced, GeNeuro SA had obtained in September 2024 a four-month provisional debt-restructuring moratorium following the Geneva Court of First Instance's approval. This provisional moratorium was then extended in January 2025 for a further four months. This procedure is aimed at facilitating the restructuring of the Company's debts and exploring solutions to ensure the continuity of its operations in the interests of all stakeholders. The decision to grant a definitive debt-restructuring moratorium of four months, extendable, granted on May 26, 2025, will allow GeNeuro SA to further its efforts to evaluate all available options, including recapitalization, advancing and/or monetizing its therapeutic assets in development, and negotiating agreements with its creditors. These efforts remain centered on maximizing value for all stakeholders and ensuring the Company's ability to continue its mission to develop innovative treatments targeting neurodegenerative and autoimmune diseases. The definitive moratorium ensures that GeNeuro SA remains protected from creditor actions while it continues to develop and implement its restructuring strategy. Any significant developments will be communicated as appropriate. The Geneva Court of First Instance judgment will be published in the Feuille d'Avis Officielle du canton de Genève and the Feuille Officielle Suisse du Commerce. Operational and Financial Updates The Commissary has approved that GeNeuro SA engages into part-time fixed term contracts with Jesús Martin Garcia and Miguel Payró, the Company’s former CEO and CFO, to continue the ongoing restructuring efforts in the interest of all stakeholders. As previously announced, the Company has decided to postpone the publication of its December 31, 2024 annual results and annual financial report in order to be able to take into account the financial impacts of the restructuring targeted by the Company as part of the granted debt-restructuring moratorium procedure. The Company will announce by press release the new date of their approval and publication.

Nochmal 10000 nachgelegt

Sehen wir heute noch die 0,10 €?